S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Catalyst Biosciences Stock Forecast, Price & News

-0.20 (-3.40 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $5.69
50-Day Range
MA: $6.34
52-Week Range
Now: $5.69
Volume437,198 shs
Average Volume568,774 shs
Market Capitalization$125.74 million
P/E RatioN/A
Dividend YieldN/A
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Catalyst Biosciences logo


CBIO Jun 2021 10.000 put
February 8, 2021 |  au.finance.yahoo.com
CBIO Mar 2021 7.500 call
February 8, 2021 |  au.finance.yahoo.com
CBIO Jan 2021 7.500 call
December 26, 2020 |  au.finance.yahoo.com
Is CBIO A Good Stock To Buy Now?
December 15, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CBIO
Year FoundedN/A



Sales & Book Value

Annual Sales$10,000.00
Price / Sales12,573.76
Book Value$5.68 per share


Net Income$-55,180,000.00


Market Cap$125.74 million
Next Earnings Date5/10/2021 (Estimated)


Overall MarketRank

1.39 out of 5 stars

Medical Sector

629th out of 1,969 stocks

Pharmaceutical Preparations Industry

301st out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
-0.20 (-3.40 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

Is Catalyst Biosciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Catalyst Biosciences stock.
View analyst ratings for Catalyst Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Catalyst Biosciences?

Wall Street analysts have given Catalyst Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catalyst Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Catalyst Biosciences

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) posted its quarterly earnings results on Wednesday, March, 3rd. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.86).
View Catalyst Biosciences' earnings history

How has Catalyst Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Catalyst Biosciences' stock was trading at $4.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CBIO shares have increased by 17.8% and is now trading at $5.69.
View which stocks have been most impacted by COVID-19

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences shares reverse split on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CBIO?

4 equities research analysts have issued twelve-month price targets for Catalyst Biosciences' shares. Their forecasts range from $15.00 to $18.00. On average, they anticipate Catalyst Biosciences' stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 198.8% from the stock's current price.
View analysts' price targets for Catalyst Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the following people:
  • Dr. Nassim Usman, Pres, CEO & Director (Age 61, Pay $743.5k)
  • Dr. Howard Levy, Chief Medical Officer (Age 67, Pay $533.74k)
  • Mr. Clinton Musil, Chief Financial Officer (Age 39)
  • Ms. Ana Kapor, Sr. Director of Investor Relations & Corp. Communications
  • Dr. Tom Knudsen D.V.M., Ph.D., VP of Corp. Devel.
  • Ms. Amanda Hill, Sr. Director of HR
  • Dr. Grant Blouse, Sr. VP of Translational Research
  • Mr. Charles J. Democko, Sr. VP of Regulatory Affairs & Quality (Age 66)
  • Dr. Anju Chatterji Ph.D., Sr. VP of Biologics Devel. & Manufacturing

Who are some of Catalyst Biosciences' key competitors?

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Celsion (CLSN).

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Acuta Capital Partners LLC (6.14%), BlackRock Inc. (6.10%), Stonepine Capital Management LLC (3.78%), Dimensional Fund Advisors LP (3.58%), Northern Trust Corp (1.39%) and Verition Fund Management LLC (1.37%). Company insiders that own Catalyst Biosciences stock include Eddie Williams, Howard Levy, John P Richard, Nassim Usman and Veronica Cai.
View institutional ownership trends for Catalyst Biosciences

Which major investors are selling Catalyst Biosciences stock?

CBIO stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Acuta Capital Partners LLC, Renaissance Technologies LLC, Worth Venture Partners LLC, Northern Trust Corp, and Barclays PLC.
View insider buying and selling activity for Catalyst Biosciences
or view top insider-selling stocks.

Which major investors are buying Catalyst Biosciences stock?

CBIO stock was acquired by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, Opaleye Management Inc., BlackRock Inc., Russell Investments Group Ltd., Wells Fargo & Company MN, CI Investments Inc., Raymond James Financial Services Advisors Inc., and JPMorgan Chase & Co.. Company insiders that have bought Catalyst Biosciences stock in the last two years include Eddie Williams, Howard Levy, John P Richard, Nassim Usman, and Veronica Cai.
View insider buying and selling activity for Catalyst Biosciences
or or view top insider-buying stocks.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $5.69.

How much money does Catalyst Biosciences make?

Catalyst Biosciences has a market capitalization of $125.74 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($4.60) on an earnings per share basis.

How many employees does Catalyst Biosciences have?

Catalyst Biosciences employs 34 workers across the globe.

What is Catalyst Biosciences' official website?

The official website for Catalyst Biosciences is www.catalystbiosciences.com.

Where are Catalyst Biosciences' headquarters?

Catalyst Biosciences is headquartered at 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]

This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.